Howard B Cottam

This inventor holds 31 USPTO granted patents and 10 published patent applications and 3 EPO patents. Top assignees: University of California, Immune Modulation, Inc., Brigham Young University. Active years: 1989-2020.

USPTO Granted Patents = 31 (Patent Applications = 10)

% Patents Active = 67.7

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 3.3

ph-index = 12

Forward Citations = 552(Granted Patents)

Location History:

Fallbrook, CA (US) (1989 - 2003)
Escondido, CA (US) (2001 - 2020)

Company Filing History:

23 out of 15,964

University of California

patents

5 out of 8

Immune Modulation, Inc.

patents

2 out of 479

Brigham Young University

patents

4. 1 out of 834,307

Other

patents

Years Active: 1989-2020

Loading Chart...

Areas of Expertise:

Neurodegenerative Diseases

TLR Agonists

Apoptosis Inhibitors

Indole Compounds

Stent-Coating Agents

Thiazolopyrimidines

Ceramide-Mediated Signal Transduction

Immunosuppression

Cancer Treatment

Chronic Lymphocytic Leukemia

Prostate Cancer

Cell Proliferation Inhibition

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10857122 - Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases (2020-12-08),

2. 9505768 - Compositions and methods for modulating TLR4 (2016-11-29),

3. 9359360 - TLR agonists (2016-06-07),

4. 9050376 - Conjugates of synthetic TLR agonists and uses therefor (2015-06-09),

5. 8846697 - Purine analogs (2014-09-30),

6. 8790655 - Conjugates of synthetic TLR agonists and uses therefor (2014-07-29),

7. 8729088 - Toll-like receptor modulators and treatment of diseases (2014-05-20),

8. 8124654 - Derivatives of hypoestoxide and related compounds (2012-02-28),

9. 7816352 - Apoptosis inhibitors (2010-10-19),

10. 7601846 - Compounds having activity as inhibitors of apoptosis (2009-10-13),

11. 7361680 - Indole compounds useful for the treatment of cancer (2008-04-22),

12. 7229979 - Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents (2007-06-12),

13. 7189752 - Use of etodolac for the treatment of chronic lymphocytic leukemia (2007-03-13),

14. 7151100 - Indole compounds useful for the treatment of cancer (2006-12-19),

15. 7129262 - Indole compounds useful for the treatment of cancer (2006-10-31),

Title: Pioneering the Future: The Inventor Howard B Cottam

Introduction:

Howard B Cottam, a visionary inventor hailing from Fallbrook, California, has left an indelible mark on the world of innovation. With an impressive portfolio of 31 patents to his name, he has revolutionized the field of neurodegenerative disease treatment.

Latest Patents:

Cottam's latest patents focus on the groundbreaking use of hypoestoxide, its derivatives, and related compounds for the treatment and prevention of neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's. His inventions offer hope for effectively treating these debilitating illnesses and potentially preventing their onset in predisposed individuals.

Career Highlights:

Throughout his illustrious career, Howard B Cottam has worked with esteemed institutions such as the University of California and Immune Modulation, Inc. His dedication to pushing the boundaries of medical science has led to the development of innovative treatment methods that have the potential to improve countless lives.

Collaborations:

Cottam's impactful work would not have been possible without the collaboration of like-minded individuals such as Dennis A Carson and Lorenzo M Leoni. Together, they have paved the way for advancements in the field of neurodegenerative disease research and treatment.

Conclusion:

In conclusion, Howard B Cottam stands as a visionary inventor whose work continues to inspire and drive progress in the world of innovation. His relentless pursuit of excellence and commitment to creating a better future through his inventions make him a true pioneer in his field. The legacy of Cottam's contributions to the fight against neurodegenerative diseases will undoubtedly shape the landscape of healthcare for years to come.